Does metabolic syndrome influence outcome following percutaneous coronary intervention?

Angiology

Volumn 62, Issue 6, 2011, Pages 437-439

  Katsiki, Niki ^a   Athyros, Vasilios G ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

diabetes; drug eluting stent; metabolic syndrome; percutaneous coronary intervention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADVERSE OUTCOME; BARE METAL STENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG ELUTING STENT; EDITORIAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR ADVERSE CARDIOVASCULAR EVENT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; HUMANS; METABOLIC SYNDROME X; TREATMENT OUTCOME;

EID: 79960945047     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319710394166     Document Type: Editorial

References (31)

1. Hu B., Zhou Y., Liu Y., et al. Impact of metabolic syndrome on clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease. Angiology. 2011 ;IN PRESS.
2. Athyros VG, Gossios TD, Tziomalos K., Florentin M., Karagiannis A., Mikhailidis DP Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci. 2010 ; in press.
3. Iturry-Yamamoto GR, Zago AC, et al. Impact of metabolic syndrome and C-reactive protein on outcome after coronary stenting. J Endocrinol Invest. 2009 ; 32 (4). 383-386.
4. Milionis HJ, Kostapanos MS, Liberopoulos EN, et al. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract. 2007 ; 61 (4). 545-551. (Pubitemid 46449817)
5. Athyros VG, Ganotakis ES, Tziomalos K., et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin. 2010 ; 26 (3). 713-719.
6. Chimonas T., Athyros VG, Ganotakis E., et al. Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology. 2010 ; 61 (1). 49-57.
7. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin. 2004 ; 20 (11). 1691-1701. (Pubitemid 39611929)
8. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing them metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1655.
9. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007 ; 49 (12). 1272-1278. (Pubitemid 46467240)
10. Briguori C., Visconti G., Focaccio A., et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009 ; 54 (23). 2157-2163.
11. Athyros VG, Tziomalos K., Florentin M., Karagiannis A., Mikhailidis DP Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin. 201 0; 26 (4). 839-842.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
13. Smith SC Jr, Allen J., Blair SN, et al. AHA/ACC Guidelines for secondary prevention of patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation. 2006 ; 113: 2363-2372. (Pubitemid 43947981)
14. Protack CD, Bakken AM, Xu J., Saad WA, Lumsden AB, Davies MG Metabolic syndrome: a predictor of adverse outcomes after carotid revascularization. J Vasc Surg. 2009 ; 49 (5). 1172 ; e1-1180.e1; discussion 1180.
15. Davies MG, Saad WE, Bismuth J., Naoum JJ, Peden EK, Lumsden AB Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting. J Vasc Surg. 2010 ; 51 (4). 926-932.
16. Paraskevas KI, Anastasakis E., Andrikopoulou M., Mikhailidis DP Radial artery catheterization for percutaneous vascular or coronary interventions: an innocent procedure? Angiology. 2010 ; 61 (1). 5-7.
17. Zhenxian Yan, Yujie Zhou, Yingxin Zhao, Zhiming Zhou, Shiwei Yang, Zhijian Wang. Impact of transradial coronary procedures on radial artery. Angiology. 2010 ; 61 (1). 8-13.
18. Lee MS, Yang T., Dhoot J., Iqbal Z., Liao H. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. Am J Cardiol. 2010 ; 105 (11). 1540-1544.
19. Aronson D., Edelman ER Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010 ; 11 (1). 75-86.
20. Kapur A., Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial J Am Coll Cardiol. 2010 ; 55 (5). 432-440.
21. Lasala JM, Cox DA, Morris DL, et al. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. Am J Cardiol. 2009 ; 103 (12). 1663-1671.
22. Novack V., Tsyvine D., Cohen DJ, et al. Multivessel drug-eluting stenting and impact of diabetes mellitus-a report from the EVENT registry. Catheter Cardiovasc Interv. 2009 ; 73 (7). 874-880.
23. Lee SW, Chun KJ, Park SW, et al. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol. 2010 ; 105 (2). 168-173.
24. Talarico GP, Brancati M., Burzotta F., et al. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. J Cardiovasc Med (Hagerstown). 2009 ; 10 (3). 245-251.
25. Arora R., Sowers JR, Saunders E., Probstfield J., Lazar HL Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery. J Card Surg. 2006 ; 21 (2). 198-204.
26. Koch CG, Weng YS, Zhou SX, et al. Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. Prevalence of risk factors, and not gender per se, determines short- and long-term survival after coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2003 ; 17 (5). 585-593. (Pubitemid 37296622)
27. Herlitz J., Brandrup-Wognsen G., Caidahl K., et al. Improvement and factors associated with improvement in quality of life during 10 years after coronary artery bypass grafting. Coron Artery Dis. 2003 ; 14 (7). 509-517. (Pubitemid 38102006)
28. Ueda H., Mitsusada N., Harimoto K., Miyawaki M., Yasuga Y., Hiraoka H. Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology. 2010 ; 116 (1). 51-57.
29. Piatti P., Di Mario C., Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003 ; 108 (17). 2074-2081. (Pubitemid 37337582)
30. Nishio K., Shigemitsu M., Kodama Y., Konno N., Katagiri T., Kobayashi Y. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with type 2 diabetes mellitus. Cardiovasc Revasc Med. 2009 ; 10 (1). 5-11.
31. Katsiki N., Mikhailidis DP, Athyros VG, Hatzitolios AI, Karagiannis A., Banach M. Are we getting to lipid targets in real life ? Arch Med Sci. 2010 ; 6: 639-641.